secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000012208-24-000008
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q4 sales down 6.7% YoY; Life Science segment declines 19.1%
-------------------------------------------------------------------

- Q4 net sales $681.2M, down 6.7% YoY; currency-neutral sales down 7.7%.
- Life Science segment sales $291.1M, down 19.1% YoY on broad-based weakness.
- Clinical Diagnostics segment sales $389.0M, up 5.3% YoY on diabetes and quality control demand.
- Net income $349.7M ($12.14 diluted EPS) vs $827.7M ($27.78) a year ago, impacted by Sartorius fair value changes.
- CEO cites ongoing biopharma weakness; expects gradual recovery in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/0000012208-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/bio-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000012208-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer